Nairametrics
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Get Data
    • Macro-Economic News
    • Research Analysis
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Get Data
    • Macro-Economic News
    • Research Analysis
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
Nairametrics
No Result
View All Result
Home Business News Coronavirus

FDA approval of the Covid-19 vaccine could drive vaccinations in US

Chidinma Anyalewechi by Chidinma Anyalewechi
August 10, 2021
in Coronavirus
Covid-19: AstraZeneca vaccine gets huge boost, produces immune response in elderly, Vaccine, COVID-19: Russia to roll out vaccine in September ahead of the West 

Covid-19: AstraZeneca vaccine gets huge boost, produces immune response in elderly

Share on FacebookShare on TwitterShare on Linkedin

Pfizer’s Covid-19 vaccine is currently only authorized for emergency use in the United States, however, its full approval by the US Food and Drug Administration could happen within weeks and this could alter the course of the pandemic in several ways.

First, the full approval, by the FDA, of a Covid-19 vaccine would persuade more people to get vaccinated and more than 30% of the eligible population in the United States still hasn’t gotten vaccinated.

This is as a result of insufficient data to convince some Americans that the vaccines are not dangerous.

RelatedPosts

Canada to ease travel requirements as COVID-19 infection rates decline

US Supreme Court blocks Biden’s vaccine mandate for large businesses

For a vaccine to qualify for emergency use authorization, their makers have to submit about three months of clinical trial data which includes at least 2 months of safety data on fully vaccinated participants, since most vaccine side effects occur 2-3 months after the vaccination.

The full FDA approval of a vaccine requires much more data, including safety and efficacy data generated in the real-world, outside of a clinical trial. The CDC has been tracking real-world data on the vaccines and more than 165 million people in the US are now vaccinated against the virus and this extra data may help convince more people that the vaccines are not dangerous.

An associate professor in the division of infectious disease epidemiology at Johns Hopkins Bloomberg School of Public Health, Dr David Dowdy, has said that the approval by the FDA will go a long way to reassure some people about the safety of the vaccine. He said, “For some, getting a full FDA approval will help allay that fear. Even if it’s just a relatively small number of people. Every little bit helps against this virus”.

Dr. Paul Offit, a prominent member of the FDA’s vaccine advisory committee and director of the Vaccine Education Center at the Children’s Hospital of Philadelphia, says that the agency is “working around the clock” on the approval of the Covid-19 vaccine.

According to Dr. Offit, the approval should not really matter since a large part of the population have already been vaccinated, which tells you that this is not experimental, however, he agrees that it does matter to some people who are hesitant because they are unsure on whether to view the vaccines as a licensed product or just approved through the EUA and happen to have more faith in the FDA.

“I think from the standpoint of the public, it really shouldn’t matter,” Offit said. “It’s been given to half of the American population. We have more than 300 million doses out there. This is far from experimental. We have a tremendous safety and efficacy portfolio on these vaccines — I mean, it’s more than most licensed products that are out there now.”

“I think they realize that at least there’s a psychological issue with how these vaccines are viewed, in terms of whether they’re a licensed product or just approved through EUA,” Offit added.

Related

Tags: Covid-19 vaccineDr. Paul OffitPfizerUS Food and Drug Administration

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Mega Millions
Hot forex
Cornerstone
Polaris Bank
Access Bank
Bankers Committee
First bank


FCMB




    Business News | Stock Market | Money Market | Cryptos | Financial Literacy | SME |

    Recent News

    • Citigroup says oil prices may crash to $65 by end of 2022 due to recession
    • Nigeria’s stock market closes bearish as market capitalization dips by N110 billion
    • IPOB disowns Peter Obi’s presidential bid, says he was never their member

    Follow us on social media:

    Recent News

    Crude oil, Oil down as China releases fuel reserves, Oil down as China releases fuel reserves

    Citigroup says oil prices may crash to $65 by end of 2022 due to recession

    July 5, 2022
    Bears market

    Nigeria’s stock market closes bearish as market capitalization dips by N110 billion

    July 5, 2022
    • ABOUT US
    • CONTACT US
    • PRODUCTS
    • ANDROID APP
    • iOS APP
    • DISCLAIMER
    • CAREERS
    • PRIVACY POLICY

    © 2022 Nairametrics

    No Result
    View All Result
    • Home
    • Exclusives
      • Financial Analysis
      • Corporate Stories
      • Interviews
      • Investigations
      • Metrics
    • Markets
      • Cryptos
      • Commodities
      • Equities
        • Dividends
        • Stock Market
      • Fixed Income
      • Market Views
      • Securities
    • Industries
      • Company News
      • Consumer Goods
      • Content Partners
      • Corporate deals
      • Corporate Press Releases
      • Energy
      • Entertainment
      • Financial Services
      • Hospitality & Travel
      • Manufacturing
      • Real Estate and Construction
      • Tech News
    • Economy
      • Get Data
      • Macro-Economic News
      • Research Analysis
    • Business News
    • Financial Literacy
      • Career tips
      • Personal Finance
    • Lifestyle
      • Billionaire Watch
      • Profiles
    • Opinions
      • Blurb
      • Op-Eds

    © 2022 Nairametrics

    Social Media Auto Publish Powered By : XYZScripts.com